An adverse reaction

- By Insurance Post Staff
- 29 Jun 2006
- Indicative reading time: 7 minutes

Tweet
Facebook
LinkedIn
Save this article
Send to
Print this page

While insurers in the pharmaceuticals sector remain prepared to provide a remedy for accidents, a side-effect of headline-making failures in clinical trials may be higher premiums, reports Veronica Cowan

The biosciences sector is not only one of the fastest-growing in the country, it is also important on a continental scale: the UK produces as many as 75% of the drugs in late-stage clinical trials in

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@postonline.co.uk or view our subscription options here: http://subscriptions.postonline.co.uk/subscribe

You are currently unable to print this content. Please contact info@postonline.co.uk to find out more.

You are currently unable to copy this content. Please contact info@postonline.co.uk to find out more.

You may share this content using our article tools. Printing this content is for the sole use of the Authorised User (named subscriber), as outlined in our terms and conditions - https://www.infopro-insight.com/terms-conditions/insight-subscriptions/

If you would like to purchase additional rights please email info@postonline.co.uk

You may share this content using our article tools. Copying this content is for the sole use of the Authorised User (named subscriber), as outlined in our terms and conditions - https://www.infopro-insight.com/terms-conditions/insight-subscriptions/

If you would like to purchase additional rights please email info@postonline.co.uk

Sorry, our subscription options are not loading right now

You are currently on corporate access.